21金维他品牌怎么样 申请店铺

更新时间:2023-06-02
21金维他是哪个国家的品牌?「21金维他」是杭州赛诺菲民生健康药业有限公司旗下著名品牌。该品牌发源于浙江,由创始人张海敏在2009期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
21金维他怎么样

21金维他,1984年上市,是中国率先上市的多维元素产品。根据中国人营养状况和饮食习惯科学配比,均衡补充人体所需的21维生素和矿物质,采用国际一流生产线生产的健康产品。

“21金维他”是一种主要原料由21种维生素和微量元素组成的药品,是一种高级的维生素补充剂。21金维他里面含有维生素C和E,维生素C可以美白,增强抵抗力,抗衰老,维生素E有软化血管,抗衰老,美白,可以用于美容,祛除一定的斑痕。

杭州民生药业有限公司创建于1926年,是中国最早的四大西药厂之一。80余年来,民生药业一直专注于西药制药产业,见证了中国整个西药制药的历史。2006年被商务部评为第一批“中华老字号”企业。

公司主要生产处方药(抗肿瘤药、抗乙肝、心血管类)、OTC(含维生素和保健品类)、大输液(包括特种输液)以及原料药等四大品类的品种。21金维他在2004年被认定为“中国驰名商标”,并确立了在国内多维元素补充剂市场的领军品牌地位。另外公司在抗肿瘤及大输液等领域享有较高的市场声誉。

公司具有较强的产品开发能力和先进的质量保证体系。粉针剂、冻干粉针剂、大容量注射剂和片剂已获药品GMP证书。同时公司被杭州市政府有关部门确定为高效化学原料及各类新型制剂的研究和生产基地的高新技术企业。

80余年的积累和发展,民生药业成为了一家专业化、负责任的现代化制药公司,公司在2002年至2006年间成功实施了跳跃式发展战略;从2007年开始全面实施的国际化发展战略,将引领企业走向新的辉煌。打造一个经久不衰、生生不息、充满青春活力的百年民生是我们的追求!

杭州赛诺菲民生健康药业有限公司成立于2010年,是由全球领先的多元化医药健康企业赛诺菲与杭州民生药业集团共同组建的健康药业领域合资企业。这标志着赛诺菲正式进军充满活力的中国非处方药市场,同时也是全球第二大的非处方药市场。

作为全球领先的多元化医药健康企业,赛诺菲在健康药业领域通过不断并购,扩大其在全球的实力。进入中国健康药业市场成为赛诺菲支持中国预防保健事业的又一支柱。赛诺菲与长期合作的伙伴民生药业成立合资企业,旨在使21金维他®等品牌覆盖到各个市场,让更多的中国百姓享受到健康保障。

Kingvita, launched in 1984, is the first multi-dimensional element product to be launched in China. According to the scientific proportion of Chinese Nutrition and diet habits, we should supplement the 21 vitamins and minerals needed by human body in a balanced way, and adopt the health products produced by the world-class production line. "21 jinvita" is a kind of medicine composed of 21 kinds of vitamins and microelements, which is a kind of advanced vitamin supplement. Jinvita contains vitamin C and E. vitamin C can whiten, enhance resistance and resist aging. Vitamin E can soften blood vessels, resist aging and whiten. It can be used for beauty and remove certain spots. Founded in 1926, Hangzhou Minsheng Pharmaceutical Co., Ltd. is one of the first four Western pharmaceutical factories in China. For more than 80 years, Minsheng pharmaceutical industry has been focusing on Western pharmaceutical industry, witnessing the history of the whole western pharmaceutical industry in China. In 2006, it was awarded the first batch of "Chinese time-honored brand" enterprises by the Ministry of Commerce. The company mainly produces prescription drugs (anti-tumor drugs, anti hepatitis B drugs, cardiovascular drugs), OTC (including vitamins and health care products), large infusion (including special infusion) and APIs. In 2004, kingvita was recognized as "China's well-known trademark" and established its leading brand position in the domestic multi-dimensional element supplement market. In addition, the company enjoys a high market reputation in the fields of anti-tumor and infusion. The company has strong product development ability and advanced quality assurance system. Powder injection, freeze-dried powder injection, large volume injection and tablet have obtained GMP certificate. At the same time, the company is determined by the relevant departments of Hangzhou municipal government as a high-tech enterprise in the research and production base of high-efficiency chemical raw materials and various new preparations. With more than 80 years of accumulation and development, Minsheng pharmaceutical industry has become a professional and responsible modern pharmaceutical company. From 2002 to 2006, Minsheng pharmaceutical successfully implemented the leaping development strategy. The international development strategy, which has been fully implemented since 2007, will lead the enterprise to a new glory. It is our pursuit to build a centenary people's livelihood that is enduring, endless and full of youth and vitality! Hangzhou Sanofi Minsheng Health Pharmaceutical Co., Ltd., founded in 2010, is a joint venture in the field of health pharmaceutical jointly established by Sanofi, a global leading diversified pharmaceutical and health enterprise, and Hangzhou Minsheng Pharmaceutical Group. This marks Sanofi's official entry into the dynamic Chinese over-the-counter drug market, which is also the second largest over-the-counter drug market in the world. As a leading diversified medical and health enterprise in the world, Sanofi expands its global strength through continuous M & A in the field of health medicine. Entering the Chinese health pharmaceutical market has become another pillar of Sanofi's support for China's prevention and health care. Sanofi has set up a joint venture with Minsheng pharmaceutical, a long-term partner, aiming to make 21 jinvita ® and other brands reach all markets and more Chinese people enjoy health protection.

本文链接: https://brand.waitui.com/0d30c126b.html 联系电话:400-816-9997

7×24h 快讯

国轩高科或将在摩洛哥建造电池工厂,年产能100GWh

从国轩高科方面了解到,国轩高科正有意向在北非国家摩洛哥建立一家电动汽车电池厂,年产能长远规划为100GWh。国轩高科方面相关负责人表示,“公司与摩洛哥政府都有在当地建电池工厂的意向,目前还在沟通中。”之所以选择摩洛哥,“是考虑到欧非大区的市场。”另据外媒报道,工厂最终投资额或高达63亿美元。(澎湃)

2小时前

深交所拟修订GDR上市交易暂行办法

深交所拟修订《深圳证券交易所与境外证券交易所互联互通存托凭证上市交易暂行办法》,现向社会公开征求意见。深交所在《暂行办法》中增加了GDR境内新增基础股票上市条件及发行审核相关安排,并明确了上市公司在筹划及境外发行GDR阶段的信息披露要求。(证券时报)

2小时前

快手大家电行业迎618开门红,单日GMV同比增长超40倍

36氪获悉,快手大家电行业迎618购物节开门红。6月1日当天,快手大家电行业单日GMV破亿,同比去年增长42倍。其中,单日GMV破百万商家数达15家,冰箱、洗衣机、空调类产品GMV同比增长73倍,电视机类产品风控后GMV同比增长40倍。

2小时前

兴业科技:拟越南设合资公司,完善东南亚市场布局

36氪获悉,兴业科技发布公告称,公司全资子公司兴业投资国际与刘里焱签署《投资合作协议》,在越南共同投资设立兴业吉丰贸易实业有限公司,兴业吉丰注册资本为50亿越南盾,其中兴业投资国际出资25.5亿越南盾(折合人民币77.03万元),持股比例51%。兴业吉丰的主要经营范围为生产、销售运动系列及休闲系列的皮革。兴业科技表示,此次在越南投资设立兴业吉丰,有利于完善公司在东南亚市场的布局。

2小时前

我国民用无人机领域首项国标发布

据市场监管总局消息,近日,市场监管总局(标准委)发布了《民用无人驾驶航空器系统安全要求》强制性国家标准(GB 42590-2023),该标准由工业和信息化部组织起草,将于2024年6月1日实施。该标准是我国民用无人机领域首项强制性国家标准,适用于除航模之外的微型、轻型和小型民用无人机,提出了电子围栏、远程识别、应急处置、结构强度等17个方面的强制性技术要求及相应的试验方法。(界面)

2小时前

本页详细列出关于21金维他的品牌信息,含品牌所属公司介绍,21金维他所处行业的品牌地位及优势。
咨询